Please login to the form below

Not currently logged in
Email:
Password:

gemcitabine

This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.

Keytruda monotherapy fails in triple negative breast cancer

Keytruda monotherapy fails in triple negative breast cancer

By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine). ... One such study is Keynote-355, which looks

Latest news

More from news
Approximately 1 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Battling breast cancer with precision medicine (Part 2)

    I wanted her to access the best treatment possible. I also knew that carboplatin was especially effective when used with another chemotherapy called gemcitabine, as the two drugs are known to ... tested the PARP inhibitor with the gemcitabine-carboplatin

  • World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

    Unfortunately, recurrence rates in high-grade ovarian cancer mean that platinum resistance is a very real possibility, leaving second-line treatment such as gemcitabine, topotecan or liposomal doxorubicin less effective over

  • Marketing strategy in complex environments

    cells. A good example of this is the combined use of  Abraxane  and  gemcitabine  in the treatment of  metastatic adenocarcinoma  of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages  apoptosis  of cell

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics